Actelion Raises Full-Year Profit Forecast on Opsumit
This article is for subscribers only.
Actelion Ltd. raised its full-year profit forecast after reporting second-quarter earnings that beat analysts’ estimates because of lower-than-expected Medicaid rebates in the U.S. on its older lung drug Tracleer.
Core earnings will increase at least in the mid-teen percentage range this year, compared with a previous forecast for growth by a low single-digit percentage, Allschwil, Switzerland-based Actelion said in a statement today. The company said it will review its 2015 forecast early next year after predicting profit growth by a single-digit percentage.